Sign in

    Paragon 28 Inc (FNA)

    Q1 2024 Summary

    Published Jan 29, 2025, 1:44 PM UTC
    Initial Price$12.25January 1, 2024
    Final Price$12.05April 1, 2024
    Price Change$-0.20
    % Change-1.63%

    What went well

    • Strong revenue growth and confidence in guidance: Paragon 28 reported record Q1 2024 revenue of $61.1 million, showing 17.4% constant currency growth over a strong Q1 2023 comp of 27% growth. The company also saw a sequential step-up from Q4 to Q1, which is uncommon and indicates strong momentum. Management reaffirmed their full-year 2024 revenue guidance of $249 million to $259 million, representing 15.1% to 19.7% growth, expressing confidence in achieving these numbers. ,
    • Positive reception of new product launches and strong pipeline: The company's recent product launches in high-growth areas like bunion and forefoot have generated significant excitement and are expected to contribute meaningfully to revenue in the latter half of 2024 and beyond. The products are exceeding expectations, and Paragon 28 has over 25 active projects in development, including several tied to SMART 28, positioning the company well for sustainable long-term growth. , ,
    • Strategic investments driving future growth: Paragon 28 has made purposeful investments in expanding their commercial team and R&D to accelerate growth. The company increased their U.S. producing sales rep roster by 6% and saw an 8% increase in productivity, with a 12% increase in their surgeon customer base. Management expects these investments to help the company grow faster and to generate operating leverage over time, leading to improved profitability. , ,

    What went wrong

    • Delayed EBITDA breakeven expectation: The company has slightly pushed out its expectation for EBITDA breakeven in 2024, indicating a longer path to profitability. ,
    • High operating expenses impacting profitability: Selling, general, and administrative expenses increased by $10.4 million or 23.7%, accounting for 88.8% of net revenue compared to 84.2% in the prior year period. This significant expense level is affecting profitability despite plans to leverage these investments over time. , ,
    • Softness in U.S. revenue growth: U.S. revenues were described as "a little light even considering the selling day and the comp impact in Q1", potentially indicating weakness in the core U.S. market.

    Q&A Summary

    1. EBITDA Timeline and Investments
      Q: Has the EBITDA breakeven been pushed to 2025 due to investments?
      A: The company acknowledged a slight push in the EBITDA breakeven timeline but emphasized that the investments made in Q1 were to help grow faster. They invested in the commercial team and R&D, committed to spending every dollar to improve the business and drive growth. They are always looking for efficiencies to manage capital better and expect to leverage these investments for sequential improvement over the year.

    2. Sales Guidance and Confidence
      Q: Is there any change to the revenue guidance for the year?
      A: The company remains confident in the revenue guidance set out in February, expecting net revenue between $249 million to $259 million, representing growth of 15.1% to 19.7%. Assumptions haven't changed, and they are thrilled with the Q1 performance, which saw an uptick versus Q4 despite fewer selling days.

    3. SG&A Expenses and Operating Leverage
      Q: How should we view the SG&A spending and its impact on profitability?
      A: SG&A expenses increased due to investments in the sales force, R&D, and professional services. However, the company expects to start leveraging these investments, reducing operating expenses as a percentage of revenue over sequential quarters. They anticipate improved efficiencies and operating leverage as revenue grows.

    4. Sales Force Expansion
      Q: What is driving the investment in sales force expansion?
      A: The excitement generated by new product launches has opened up opportunities to bring on talented salespeople. The company is committed to investing in the right partners who align with their clinically oriented approach. These investments are aimed at helping the company grow faster and are expected to contribute to future revenue growth, both domestically and internationally.

    5. New Product Contributions
      Q: When will new products contribute meaningfully to revenue?
      A: While recently launched products are already generating momentum, the company expects more meaningful contributions from them in the latter half of the year and into next year. The reception has exceeded expectations, and upcoming launches like the SMART 28 are on plan and expected to perform well.

    6. Bunion Market Growth
      Q: Are new bunion products gaining market share?
      A: Yes, the company's forefoot franchise, including new products like the MIS bunion portfolio and the BunYo-Matic, is growing nicely and taking market share. These products have been well received, exceeding expectations, and are hitting a sweet spot with patients' interests. The company has high aspirations for upcoming launches in this segment.

    7. International Business Performance
      Q: Is international growth driving overall revenue growth?
      A: The international business is performing exceptionally well, with higher growth rates than the U.S., though on a smaller scale. Investments in the international business are paying off, and the company is thrilled with the global reception of their products. They view global participation as essential to their mission.

    Related Publications